Guillain-Barré Syndrome following Treatment with Sunitinib Malate.
Autor(es): Kanaan Ziad; Kulairi Zain; Titianu Mirela; Saha Sandip; Kumar Sarwan
Resumo: Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)-resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib's inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different neuropathies. We hereby report an interesting case of Guillain-Barré syndrome in a middle-aged patient with metastatic renal cell carcinoma following sunitinib treatment.
Imprenta: Case Reports in Oncological Medicine, 2014
Identificador do objeto digital: 10.1155/2014/712040
Descritores: Guillain-Barre Syndrome - Cell
Data de publicação: 2014
